https://semaglutidewatchdog.com/research Trial summaries and dated industry news on semaglutide and GLP-1 medications. en-us Fri, 04 Sep 2026 12:00:00 +0000 https://semaglutidewatchdog.com/news/novo-cuts-self-pay-pen-pricing/https://semaglutidewatchdog.com/news/novo-cuts-self-pay-pen-pricing/Wed, 15 Jul 2026 12:00:00 +0000Direct cash pricing for the branded semaglutide pen falls far below list, narrowing the gap compounded programmes have relied on since 2023. https://semaglutidewatchdog.com/research/surmount-1/https://semaglutidewatchdog.com/research/surmount-1/Sun, 12 Jul 2026 12:00:00 +0000SURMOUNT-1 study summary: design, population, results, limitations, funding, and what the trial does not prove. New England Journal of Medicine, June 2022. https://semaglutidewatchdog.com/research/select/https://semaglutidewatchdog.com/research/select/Sun, 12 Jul 2026 12:00:00 +0000SELECT study summary: design, population, results, limitations, funding, and what the trial does not prove. New England Journal of Medicine, December 2023. https://semaglutidewatchdog.com/research/regulatory-updates/https://semaglutidewatchdog.com/research/regulatory-updates/Sun, 12 Jul 2026 12:00:00 +0000The FDA compounding timeline for semaglutide and tirzepatide - every date sourced, plus what is still live in rulemaking and litigation. https://semaglutidewatchdog.com/news/medicare-glp1-access/https://semaglutidewatchdog.com/news/medicare-glp1-access/Wed, 01 Jul 2026 12:00:00 +0000Eligible Part D beneficiaries gain a route that undercuts every compounded programme we track. https://semaglutidewatchdog.com/research/step-1/https://semaglutidewatchdog.com/research/step-1/Mon, 08 Jun 2026 12:00:00 +0000STEP-1 study summary: design, population, results, limitations, funding, and what the trial does not prove. New England Journal of Medicine, March 2021. https://semaglutidewatchdog.com/research/surmount-5/https://semaglutidewatchdog.com/research/surmount-5/Fri, 05 Jun 2026 12:00:00 +0000SURMOUNT-5 study summary: design, population, results, limitations, funding, and what the trial does not prove. New England Journal of Medicine, May 2025. https://semaglutidewatchdog.com/research/roundup-july-2026/https://semaglutidewatchdog.com/research/roundup-july-2026/Mon, 01 Jun 2026 12:00:00 +0000What changed in July 2026 in GLP-1 pricing, regulation and evidence - brand price collapse, the 503B bulks proposal, and the evidence gap in ODT products. https://semaglutidewatchdog.com/news/fda-503b-bulks-proposal/https://semaglutidewatchdog.com/news/fda-503b-bulks-proposal/Thu, 30 Apr 2026 12:00:00 +0000If finalised, outsourcing facilities would lose the pathway for compounding these molecules at scale. https://semaglutidewatchdog.com/news/wegovy-hd-7-2-mg/https://semaglutidewatchdog.com/news/wegovy-hd-7-2-mg/Wed, 15 Apr 2026 12:00:00 +0000A higher-dose option for patients who plateau at the 2.4 mg maintenance dose, priced through the manufacturer channel. https://semaglutidewatchdog.com/news/counterfeit-and-salt-form-alerts/https://semaglutidewatchdog.com/news/counterfeit-and-salt-form-alerts/Fri, 10 Apr 2026 12:00:00 +0000Two different problems with one outcome: an unverified substance in a syringe. https://semaglutidewatchdog.com/news/generic-semaglutide-abroad/https://semaglutidewatchdog.com/news/generic-semaglutide-abroad/Fri, 20 Mar 2026 12:00:00 +0000Patents lapsed across roughly ten markets in 2026. US patents run into the early 2030s. https://semaglutidewatchdog.com/news/hims-settles-exits-compounded/https://semaglutidewatchdog.com/news/hims-settles-exits-compounded/Sun, 15 Mar 2026 12:00:00 +0000Following a settlement with Novo Nordisk, one of the largest consumer platforms exits compounded semaglutide. https://semaglutidewatchdog.com/news/oral-wegovy-launch/https://semaglutidewatchdog.com/news/oral-wegovy-launch/Mon, 05 Jan 2026 12:00:00 +0000An FDA-approved tablet reaches the market inside the compounded price band, removing the main reason many patients took the compounded route. https://semaglutidewatchdog.com/news/fda-warning-letters-online-sellers/https://semaglutidewatchdog.com/news/fda-warning-letters-online-sellers/Tue, 16 Sep 2025 12:00:00 +0000The agency targeted direct-to-consumer advertising by compounded semaglutide marketers rather than product quality. https://semaglutidewatchdog.com/news/semaglutide-shortage-resolved/https://semaglutidewatchdog.com/news/semaglutide-shortage-resolved/Fri, 21 Feb 2025 12:00:00 +0000The declaration narrowed lawful compounding to the patient-specific 503A pathway and set the deadlines that reshaped the market.